Clinical Assistant Professor
McGill University, 2012, MDCM
University of British Columbia, 2015, Internal Medicine Residency
University of British Columbia, 2017, Endocrinology Fellowship
Harvard School of Public Health, 2018, MPH, Public Health and Epidemiology

1. Colsevelam as an add-on treatment for control of dyslipidemia and hyperglycaemia in Type 2 Diabetes. Sandhu S, Mandana Moosavi, Kamran Golmohammadi, Francis G. CDJ June 2015

2. Effect of autoimmunity Risk Loci on the honeymoon phase in Type 1 Diabetes; M. Moosavi, Constantin Polychronakos. Pediatric Diabetes 2017 Sep; 18(6): 459-462

3. Audit of Atypical Femoral fractures and a description of some of their features. Lian K, Sandhu S, Moosavi M, Can Assoc Radiol J, 2016 Feb 67 (1): 69-75

4. The effect of Type 2 diabetes risk loci on insulin requirements in Type 1 diabetes. M. Moosavi, Jade Seguin, Constantin Polychronakos. Horm Res Pediatric 2012; 77: 305-3085.

6. Mechanism of action of islet neogenesis associated protein ( INGAP): Comparison of the full length recombinant protein and a bio active peptide. Maria Petropavlovskaisa, Jamal Daoud, M. Moosavi, Jieping Ding, Lawrence Rosenberg. AM J Physiol Endocrinol Metab 2012 Oct 1; 303 (7); E917-27

Suite 630
221 West Esplanade
North Vancouver, BC V7M 3J3
work phone: 6047704054
work fax: 6043984222